Lymphangiogenesis-mediated sheddinq of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis

American Journal of Surgical Pathology

Volumn 29, Issue 10, 2005, Pages 1356-1366

  Kumasaka, Toshio ^a   Seyama, Kuniaki ^a   Mitani, Keiko ^a   Souma, Sanae ^a   Kashiwagi, Satoko ^a   Hebisawa, Akira ^b   Sato, Teruhiko ^a   Kubo, Hajime ^c   Gomi, Kiyoshi ^d   Shibuya, Kazutoshi ^e   Fukuchi, Yoshinosuke ^a   Suda, Koichi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^e TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Axial lymphatics; LAM cell clusters; Lymphangiogenesis; Lymphangioleiomyomatosis; Thoracic duct

Indexed keywords

ADULT; ANGIOMYOLIPOMA; ARTICLE; ASCITES; AUTOPSY; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CHYLE; DIAPHRAGM; DISEASE COURSE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPH FLOW; LYMPH NODE; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; LYMPHANGIOLEIOMYOMATOSIS; LYMPHATIC SYSTEM; MEDIASTINUM; METASTASIS; MORPHOLOGY; PLEURA EFFUSION; RETROPERITONEUM; THORACIC DUCT; TUBEROUS SCLEROSIS COMPLEX GENE; CHYLOUS ASCITES; ENDOTHELIUM CELL; FEMALE; IMMUNOHISTOCHEMISTRY; PATHOLOGY; TUMOR EMBOLISM;

ADULT; CHYLOUS ASCITES; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHANGIOGENESIS; LYMPHANGIOLEIOMYOMATOSIS; NEOPLASM CIRCULATING CELLS; NEOPLASM METASTASIS; THORACIC DUCT;

EID: 25444532780     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000172192.25295.45     Document Type: Article

References (49)

1. Astrinidis A, Cash TP, Hunter DS, et al. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene. 2002;21:8470-8476.
2. Astrinidis A, Henske EP. Aberrant cellular differentiation and migration in renal and pulmonary tuberous sclerosis complex. J Child Neurol. 2004;19:710-715.
3. Berner A, Franzen S, Heilo A. Fine needle aspiration cytology as a diagnostic approach to lymphangioleiomyomatosis: a case report. Acta Cytol. 1997;41:877-879.
4. Bernstein SM, Newell JD Jr, Adamczyk D, et al. How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? Am J Respir Crit Care Med. 1995;152:2138-2143.
5. Bettendorf U. Lymph flow mechanism of the subperitoneal diaphragmatic lymphatics. Lymphology. 1978;11:111-116.
6. Bittmann I, Dose TB, Muller C, et al. Lymphangioleiomyomatosis: recurrence after single lung transplantation. Hum Pathol. 1997;28:1420-1423.
7. Bittmann I, Rolf B, Amann G, et al. Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum Pathol. 2003;34:95-98.
8. Bush JK, McLean RL, Sieker HO. Diffuse lung disease due to lymphangiomyoma. Am J Med. 1969;46:645-654.
9. Carrington CB, Cugell DW, Gaensler EA, et al. Lymphangioleiomyomatosis: physiologic-pathologic-radiologic correlations. Am Rev Respir Dis. 1977;116:977-995.
10. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA. 2000;97:6085-6090.
11. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563-572.
12. Cornog JL Jr, Enterline HT. Lymphangiomyoma, a benign lesion of chyliferous lymphatics synonymous with lymphangiopericytoma. Cancer. 1966;19:1909-1930.
13. Corrin B, Liebow AA, Friedman PJ. Pulmonary lymphangiomyomatosis: a review. Am J Pathol. 1975;79:348-382.
14. Costello LC, Hartman TE, Ryu JH. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc. 2000;75:591-594.
15. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci USA. 2004;101:17462-17467.
16. Frack MD, Simon L, Dawson BH. The lymphangiomyomatosis syndrome. Cancer. 1968;22:428-437.
17. Franz DN, Brody A, Meyer C, et al. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med. 2001;164:661-668.
18. Hayashi T, Fleming MV, Stetler-Stevenson WG, et al. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol. 1997;28:1071-1078.
19. Henske EP. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer. 2003;38:376-381.
20. Itami M, Teshima S, Asakuma Y, et al. Pulmonary lymphangiomyomatosis diagnosed by effusion cytology: a case report. Acta Cytol. 1997;41:522-528.
21. Johnson S. Rare diseases. 1. Lymphangioleiomyomatosis: clinical features, management and basic mechanisms. Thorax. 1999;54:254-264.
22. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev. 2002;82:673-700.
23. Karbowniczek M, Astrinidis A, Balsara BR, et al. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med. 2003;167:976-982.
24. Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis. Am J Surg Pathol. 2004;28:1007-1016.
25. Leak LV, Rahil K. Permeability of the diaphragmatic mesothelium: the ultrastructural basis for 'stomata.' Am J Anat. 1978;151:557-593.
26. Li J, Jiang B. A scanning electron microscopic study on three-dimensional organization of human diaphragmatic lymphatics. Funct Dev Morphol. 1993;3:129-132.
27. Li J, Zhao Z, Zhou J, et al. A study of the three-dimensional organization of the human diaphragmatic lymphatic lacunae and lymphatic drainage units. Anat Anz. 1996;178:537-544.
28. Li JC, Yu SM. Study on the ultrastructure of the peritoneal stomata in humans. Acta Anat (Basel). 1991;141:26-30.
29. Matsui K, Takeda K, Yu ZX, et al. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med. 2000;124:267-275.
30. Miller WT, Cornog JL Jr, Sullivan MA. Lymphangiomyomatosis: a clinical-roentgenologic-pathologic syndrome. Am J Roentgenol Radium Ther Nucl Med. 1971;111:565-572.
31. Moss J, Avila NA, Barnes PM, et al. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med. 2001;164:669-671.
32. Nine JS, Yousem SA, Paradis IL, et al. Lymphangioleiomyomatosis: recurrence after lung transplantation. J Heart Lung Transplant. 1994;13:714-719.
33. O'Brien JD, Lium JH, Parosa JF, et al. Lymphangiomyomatosis recurrence in the allograft after single-lung transplantation. Am J Respir Crit Care Med. 1995;151:2033-2036.
34. Partanen TA, Arola J, Saaristo A, et al. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J. 2000;14:2087-2096.
35. Sato T, Seyama K, Fujii H, et al. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet. 2002;47:20-28.
36. Sato T, Seyama K, Kumasaka T, et al. A patient with TSC1 germline mutation whose clinical phenotype was limited to lymphangioleiomyomatosis. J Intern Med. 2004;256:166-173.
37. Seyama K, Kira S, Takahashi H, et al. Longitudinal follow-up study of 11 patients with pulmonary lymphangioleiomyomatosis: diverse clinical courses of LAM allow some patients to be treated without anti-hormone therapy. Respirology. 2001;6:331-340.
38. Shinohara H, Kominami R, Taniguchi Y, et al. The distribution and morphology of lymphatic vessels on the peritoneal surface of the adult human diaphragm, as revealed by an ink-absorption method. Okajimas Folia Anat Jpn. 2003;79:175-183.
39. Silverstein EF, Ellis K, Wolff M, et al. Pulmonary lymphangiomyomatosis. Am J Roentgenol Radium Ther Nucl Med. 1974;120:832-850.
40. Smolarek TA, Wessner LL, McCormack FX, et al. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet. 1998;62:810-815.
41. Sugino T, Kusakabe T, Hoshi N, et al. An invasion-independent pathway of blood-borne metastasis: a new murine mammary tumor model. Am J Pathol. 2002;160:1973-1980.
42. Sugino T, Yamaguchi T, Ogura G, et al. Morphological evidence for an invasion-independent metastasis pathway exists in multiple human cancers. BMC Med. 2004;2:9.
43. Tsilibary EC, Wissig SL. Absorption from the peritoneal cavity: SEM study of the mesothelium covering the peritoneal surface of the muscular portion of the diaphragm. Am J Anat. 1977;149:127-133.
44. Tsilibary EC, Wissig SL. Light and electron microscope observations of the lymphatic drainage units of the peritoneal cavity of rodents. Am J Anat. 1987;180:195-207.
45. Urban T, Lazor R, Lacronique J, et al. Pulmonary lymphangioleiomyomatosis: a study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies Orphelines' Pulmonaires (GERM'O'P). Medicine (Baltimore). 1999;78:321-337.
46. Vazquez JJ, Fernandez-Cuervo L, Fidalgo B. Lymphangiomyomatosis: morphogenetic study and ultrastructural confirmation of the histogenesis of the lung lesion. Cancer. 1976;37:2321-2328.
47. Wolff M. Lymphangiomyoma: clinicopathologic study and ultrastructural confirmation of its histogenesis. Cancer. 1973;31:988-1007.
48. Yamauchi M, Nakahara H, Uyama K, et al. Cytologic finding of chyloascites in lymphangioleiomyomatosis: a case report. Acta Cytol. 2000;44:1081-1084.
49. Zhe X, Yang Y, Jakkaraju S, et al. Tissue inhibitor of metalloproteinase-3 downregulation in lymphangioleiomyomatosis: potential consequence of abnormal serum response factor expression. Am J Respir Cell Mol Biol. 2003;28:504-511.